Article
Philadelphia-The reality of light-adjustable IOLs for clinical use is on the horizon. Availability of technology such as this will eliminate the need to remove IOLs because of incorrect power, according to Nick Mamalis, MD.
Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension
(EyePod) From idea to impact: Navigating ophthalmic innovation
Ophthalmology sees AI-powered impact on cataract and diabetic eye disease
Cleveland Clinic’s Cole Eye Institute expands with Jeffrey and Patricia Cole Pavilion